Evinacumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Evinacumab
Accession Number
DB15354
Description

Evinacumab is under investigation in clinical trial NCT03146416 (Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers).

Type
Biotech
Groups
Investigational
Purchasing individual compounds or compound libraries for your research?
Learn More
Synonyms
Not Available
External IDs
  • REGN1500

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Evinacumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Evinacumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Evinacumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Evinacumab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Anthrax immune globulin human is combined with Evinacumab.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Evinacumab.
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Evinacumab.
Asfotase alfaThe risk or severity of adverse effects can be increased when Asfotase alfa is combined with Evinacumab.
AtezolizumabThe risk or severity of adverse effects can be increased when Atezolizumab is combined with Evinacumab.
AtoltivimabThe risk or severity of adverse effects can be increased when Evinacumab is combined with Atoltivimab.
Additional Data Available
  • Extended Description
    Extended Description
    Available for Purchase

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity
    Available for Purchase

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level
    Available for Purchase

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action
    Available for Purchase

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
T8B2ORP1DW
CAS number
1446419-85-7

References

General References
Not Available
Wikipedia
Evinacumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentHomozygous Familial Hypercholesterolemia1
3Enrolling by InvitationTreatmentHomozygous Familial Hypercholesterolemia1
3RecruitingTreatmentHomozygous Familial Hypercholesterolemia1
2Active Not RecruitingTreatmentHigh Cholesterol1
2CompletedTreatmentHomozygous Familial Hypercholesterolemia1
2CompletedTreatmentSevere Hypertriglyceridemia (sHTG)1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedTreatmentHypertriglyceridemias1
1CompletedTreatmentMetabolic Disorders1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 09:19 / Updated on June 12, 2020 10:53

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates